ALZAMEND NEURO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ALZAMEND NEURO, INC. (ALZN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.33 per share for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-22
- ALZAMEND NEURO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-07-31 was $2.92.
- ALZAMEND NEURO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2026 was $2.33.
- ALZAMEND NEURO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2000000.00, a 73542830.69% increase from fiscal 2022.
- ALZAMEND NEURO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $2.72, a 81.30% increase from fiscal 2021.
- ALZAMEND NEURO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $1.50, a 5.14% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-04-30 | $2.33 10-K · filed 2026-07-22 | |||
| 2023-04-30 | $2000000.00 10-K · filed 2023-07-27 | |||
| 2023-01-31 | $2000000.00 10-Q · filed 2023-03-15 | |||
| 2022-04-30 | $2.72 10-K · filed 2022-07-19 | |||
| 2022-01-31 | $2.92 10-Q · filed 2022-03-15 | |||
| 2021-10-31 | $2.92 10-Q · filed 2021-12-13 | |||
| 2021-07-31 | $2.92 10-Q · filed 2021-09-13 | |||
| 2021-04-30 | $1.50 10-K · filed 2022-07-19 | |||
| 2020-04-30 | $1.43 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |